Cure8 research brief
RDW-CV, a routine blood-test parameter, may help signal higher inflammatory activity in ulcerative colitis and provide low-cost adjunctive information when assessing disease activity.
Clinicians who care for IBD patients, researchers studying blood-based biomarkers, and adult patients with UC interested in noninvasive activity markers.
This was a retrospective single-center analysis of 455 IBD patients (365 UC, 90 CD) using standard disease activity indices and archived blood-test results.
The key finding is that RDW-CV correlated with higher activity in UC across severity categories and was higher in active vs remission UC; in CD the association was weaker and apparent only across categories, not when simply comparing remission vs active disease.
How people might use this: RDW is an inexpensive part of a complete blood count that could provide supportive information about inflammatory burden alongside established markers (CRP, fecal calprotectin) and clinical assessment — especially where endoscopy is not available.
The authors recommend prospective multicenter validation before RDW is used routinely to guide decisions. Study limits: The retrospective single-center design, imbalance in UC vs CD sample sizes, and lack of prospective validation mean these results are preliminary. The article itself calls for larger prospective studies to confirm clinical utility.
This is a retrospective single-center study; RDW-CV showed stronger associations in UC than CD and RDW-SD was not useful. The authors recommend prospective multicenter validation before changing clinical practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
